Abstract
Providers and patients encounter challenges related to the management of Variants of Unknown Significance (VUS). A VUS introduces new counseling dilemmas for the understanding and psychosocial impact of uncertain genetic test results. This descriptive study uses Mishel’s theory of uncertainty in illness to explore the experience of individuals who have received a VUS as part of the genetic testing process. Semi-structured interviews were conducted with 27 adult individuals who received a VUS for Lynch syndrome mismatch repair genes between 2002 and 2013. The interviews were transcribed and analyzed. Most individuals recalled their result and perceived various types of uncertainty associated with their VUS. Half of the participants appraised their variant as a danger and implemented coping strategies to reduce the threat of developing cancer. Mobilizing strategies to reduce their risk included vigilant cancer surveillance, information seeking and notifying relatives. The majority of participants were unaware of the possibility of a VUS before receiving their result and expected reclassification over time. These results provide insight into the ways healthcare providers can support patients who receive VUS for Lynch syndrome. Findings also provide direction for future work that can further explicate the impact of receiving a VUS.
Similar content being viewed by others
References
Aaltonen, L. A., Salovaara, R., Kristo, P., Canzian, F., Hemminki, A., Peltomaki, P., et al. (1998). Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. The New England Journal of Medicine, 338, 1481–1487.
Babrow, A. S., Kasch, C. R., & Ford, L. A. (1998). The many meanings of uncertainty in illness: toward a systematic accounting. Health Communication, 10(1), 1–23. doi:10.1207/s15327027hc1001_1.
Barnetson, R. A., Tenesa, A., Farrington, S. M., Nicholl, I. D., Cetnarskyj, R., Porteous, M. E., et al. (2006). Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. The New England Journal of Medicine, 354(26), 2751–2763. doi:10.1056/NEJMoa053493.
Blazer, K. (2013). Essential Elements of Genetic Cancer Risk Assessment, Counseling and Communication for Patients and Families. Paper presented at the Instituto Nacional de Cancerología (INCAN), Mexico City, MX.
Bradbury, A. R., Patrick-Miller, L., Long, J., Powers, J., Stopfer, J., Forman, A., et al. (2015). Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility. Genetics in Medicine, 17(6), 485–492. doi:10.1038/gim.2014.134.
Braddock 3rd, C. H., Edwards, K. A., Hasenberg, N. M., Laidley, T. L., & Levinson, W. (1999). Informed decision making in outpatient practice: time to get back to basics. JAMA, 282(24), 2313–2320.
Culver, J. O., Brinkerhoff, C. D., Clague, J., Yang, K., Singh, K., Sand, S. R., & Weitzel, J. N. (2013). Variants of uncertain significance in BRCA testing: evaluation of surgical decisions, risk perception, and cancer distress. Clinical Genetics, 84(5), 464–472. doi:10.1111/cge.12097.
Cypowyj, C., Eisinger, F., Huiart, L., Sobol, H., Morin, M., & Julian-Reynier, C. (2009). Subjective interpretation of inconclusive BRCA1/2 cancer genetic test results and transmission of information to the relatives. Psychooncology, 18(2), 209–215. doi:10.1002/pon.1407.
Dorval, M., Patenaude, A. F., Schneider, K. A., Kieffer, S. A., DiGianni, L., Kalkbrenner, K. J., et al. (2000). Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility: findings from p53 and BRCA1 testing programs. Journal of Clinical Oncology, 18, 2135–2142.
Eccles, B. K., Copson, E., Maishman, T., Abraham, J. E., & Eccles, D. M. (2015). Understanding of BRCA VUS genetic results by breast cancer specialists. BMC Cancer, 15, 936. doi:10.1186/s12885-015-1934-1.
Frey, M. K., Kim, S. H., Bassett, R. Y., Martineau, J., Dalton, E., Chern, J.-Y., & Blank, S. V. (2015). Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent non-informative genetic screening. Gynecologic Oncology, 139(2), 211–215. doi:10.1016/j.ygyno.2015.08.006.
Frost, C. J., Venne, V., Cunningham, D., & Gerritsen-McKane, R. (2004). Decision making with uncertain information: learning from women in a high risk breast cancer clinic. Journal of Genetic Counseling, 13(3), 221–236. doi:10.1023/B:JOGC.0000027958.02383.a9.
Giardiello, F. M., Allen, J. I., Axilbund, J. E., Boland, C. R., Burke, C. A., Burt, R. W., et al. (2014). Guidelines on genetic evaluation and management of lynch syndrome: a consensus statement by the US multi-society task force on colorectal cancer. The American Journal of Gastroenterology, 109(8), 1159–1179. doi:10.1038/ajg.2014.186.
Glaser, B. G. (1969). The constant comparison method of qualitative analysis. Reading, MA: Addison-Wesley.
Hallowell, N., Foster, C., Ardern-Jones, A., Eeles, R., Murday, V., & Watson, M. (2002). Genetic testing for women previously diagnosed with breast/ovarian cancer: examining the impact of BRCA1 and BRCA2 mutation searching. Genetic Testing, 6(2), 79–87. doi:10.1089/10906570260199320.
Hampel, H., Frankel, W. L., Martin, E., Arnold, M., Khanduja, K., Kuebler, P., et al. (2005). Screening for the lynch syndrome (hereditary nonpolyposis colorectal cancer). The New England Journal of Medicine, 352(18), 1851–1860.
Han, P. K., Klein, W. M., & Arora, N. K. (2011). Varieties of uncertainty in health care: a conceptual taxonomy. Medical Decision Making, 31(6), 828–838. doi:10.1177/0272989x11393976.
Henry, M. S. (2006). Uncertainty, responsibility, and the evolution of the physician/patient relationship. Journal of Medical Ethics, 32(6), 321–323. doi:10.1136/jme.2005.013987.
Hilbers, F. S., Vreeswijk, M. P., van Asperen, C. J., & Devilee, P. (2013). The impact of next generation sequencing on the analysis of breast cancer susceptibility: a role for extremely rare genetic variation? Clinical Genetics, 84(5), 407–414. doi:10.1111/cge.12256.
LaDuca, H., Stuenkel, A. J., Dolinsky, J. S., Keiles, S., Tandy, S., Pesaran, T., et al. (2014). Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genetics in Medicine, 16(11), 830–837. doi:10.1038/gim.2014.40.
Luther, V. P., & Crandall, S. J. (2011). Commentary: ambiguity and uncertainty: neglected elements of medical education curricula? Academic Medicine, 86(7), 799–800. doi:10.1097/ACM.0b013e31821da915.
MacDonald, D. J., Sarna, L., Weitzel, J. N., & Ferrell, B. (2010). Women’s perceptions of the personal and family impact of genetic cancer risk assessment: focus group findings. Journal of Genetic Counseling, 19(2), 148–160. doi:10.1007/s10897-009-9267-3.
Marra, G., & Boland, C. R. (1995). Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. Journal of the National Cancer Institute, 87(15), 1114–1125. doi:10.1093/jnci/87.15.1114.
Mishel, M. H. (1988). Uncertainty in illness. Image - The Journal of Nursing Scholarship, 20(4), 225–232.
Murray, M. L., Cerrato, F., Bennett, R. L., & Jarvik, G. P. (2011). Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical decisions. Genetics in Medicine, 13(12), 998–1005. doi:10.1097/GIM.0b013e318226fc15.
National Cancer Institute. (2016). NCI Dictionary of Genetics Terms. NCI Dictionary. 2016, from http://www.cancer.gov/publications/dictionaries/genetics-dictionary.
Norquist, B. M., & Swisher, E. M. (2015). More genes, more problems? Benefits and risks of multiplex genetic testing. Gynecologic Oncology, 139(2), 209–210. doi:10.1016/j.ygyno.2015.10.013.
O’Brien, J. M. (2000). Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark, and Finland, by P. Lichtenstein, N.V. Holm, P.K. Verkasalo, a. Iliadou, J. Kaprio, M. Koskenvuo, E. Pukkala, a. Skytthe, and K. Hemminki. The New England Journal of Medicine, 343, 78–84 Surv Ophthalmol, 45(2), 167-168.
O’Neill, S. C., DeMarco, T., Peshkin, B. N., Rogers, S., Rispoli, J., Brown, K., et al. (2006). Tolerance for uncertainty and perceived risk among women receiving uninformative BRCA1/2 test results. American Journal of Medical Genetics. Part C, Seminars in Medical Genetics, 142C(4), 251–259. doi:10.1002/ajmg.c.30104.
Phelps, C., Wood, F., Bennett, P., Brain, K., & Gray, J. (2007). Knowledge and expectations of women undergoing cancer genetic risk assessment: a qualitative analysis of free-text questionnaire comments. Journal of Genetic Counseling, 16(4), 505–514.
Pinol, V., Castells, A., Andreu, M., Castellvi-Bel, S., Alenda, C., Llor, X., et al. (2005). Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA, 293(16), 1986–1994.
Platz, E. A., Willett, W. C., Colditz, G. A., Rimm, E. B., Spiegelman, D., & Giovannucci, E. (2000). Proportion of colon cancer risk that might be preventable in a cohort of middle-aged US men. Cancer Causes & Control, 11(7), 579–588.
Salovaara, R., Loukola, A., Kristo, P., Kaariainen, H., Ahtola, H., Eskelinen, M., et al. (2000). Population-based molecular detection of hereditary nonpolyposis colorectal cancer. Journal of Clinical Oncology, 18(11), 2193–2200.
Scherr, C. L., Lindor, N. M., Malo, T. L., Couch, F. J., & Vadaparampil, S. T. (2015a). Genetic counselors’ practices and confidence regarding variant of uncertain significance results and reclassification from BRCA testing. Clinical Genetics, 88(6), 523–529. doi:10.1111/cge.12563.
Scherr, C. L., Lindor, N. M., Malo, T. L., Couch, F. J., & Vadaparampil, S. T. (2015b). A preliminary investigation of genetic counselors/’ information needs when receiving a variant of uncertain significance result: a mixed methods study. Genetics in Medicine, 17(9), 739–746. doi:10.1038/gim.2014.185.
Siegel, R. L., Miller, K. D., & Jemal, A. (2015). Cancer statistics, 2015. CA: a Cancer Journal for Clinicians, 65(1), 5–29. doi:10.3322/caac.21254.
Siegel, R. L., Miller, K. D., & Jemal, A. (2016). Cancer statistics, 2016. CA: a Cancer Journal for Clinicians, 66(1), 7–30. doi:10.3322/caac.21332.
Strauss And Corbin, J. (1998). Basics of qualitative research: techniques and procedures for developing grounded theory (2nd ed.). Thousand Oaks, CA: Sage.
van Dijk, S., Timmermans, D. R., Meijers-Heijboer, H., Tibben, A., van Asperen, C. J., & Otten, W. (2006). Clinical characteristics affect the impact of an uninformative DNA test result: the course of worry and distress experienced by women who apply for genetic testing for breast cancer. Journal of Clinical Oncology, 24(22), 3672–3677.
van Dijk, S., van Asperen, C. J., Jacobi, C. E., Vink, G. R., Tibben, A., Breuning, M. H., & Otten, W. (2004). Variants of uncertain clinical significance as a result of BRCA1/2 testing: impact of an ambiguous breast cancer risk message. Genetic Testing, 8(3), 235–239.
van Oostrom, I., Meijers-Heijboer, H., Duivenvoorden, H. J., Bröcker-Vriends, A. H. J. T., van Asperen, C. J., Sijmons, R. H., et al. (2007). The common sense model of self-regulation and psychological adjustment to predictive genetic testing: a prospective study. Psycho-Oncology, 16(12), 1121–1129. doi:10.1002/pon.1178.
Vos, J., Jansen, A. M., Menko, F., van Asperen, C. J., Stiggelbout, A. M., & Tibben, A. (2011). Family communication matters: the impact of telling relatives about unclassified variants and uninformative DNA-test results. Genetics in Medicine, 13(4), 333–341. doi:10.1097/GIM.0b013e318204cfed.
Vos, J., Otten, W., van Asperen, C., Jansen, A., Menko, F., & Tibben, A. (2008). The counsellees’ view of an unclassified variant in BRCA1/2: recall, interpretation, and impact on life. Psycho-Oncology, 17(8), 822–830. doi:10.1002/pon.1311.
Weissman, S. M., Bellcross, C., Bittner, C. C., Freivogel, M. E., Haidle, J. L., Kaurah, P., et al. (2011). Genetic counseling considerations in the evaluation of families for lynch syndrome-a review. Journal of Genetic Counseling, 20(1), 5–19. doi:10.1007/s10897-010-9325-x.
Yorczyk, A., Robinson, L. S., & Ross, T. S. (2015). Use of panel tests in place of single gene tests in the cancer genetics clinic. Clinical Genetics, 88(3), 278–282. doi:10.1111/cge.12488.
Acknowledgements
This research was funded by the Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health. The authors wish to acknowledge Dr. Barbara B. Biesecker and Dr. Jeffrey N. Weitzel whose support, knowledge and perspectives contributed to the study. We would also like to acknowledge Lily Van Tongeren for assistance with manuscript preparation and to the study participants who shared their experiences.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Ilana Solomon, Elizabeth Harrington, Gillian Hooker, Lori Erby, Jennifer Axilbund, Heather Hampel, Kara Semotiuk, Amie Blanco, William M. P. Klein, Francis Giardiello, Lori Leonard declare that they have no conflict of interest.
Human Studies and Informed Consent
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients for being included in the study
Animal Studies
No animal studies were carried out by the authors for this article
Rights and permissions
About this article
Cite this article
Solomon, I., Harrington, E., Hooker, G. et al. Lynch Syndrome Limbo: Patient Understanding of Variants of Uncertain Significance. J Genet Counsel 26, 866–877 (2017). https://doi.org/10.1007/s10897-017-0066-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10897-017-0066-y